BBS treatment leads to decrease in p53 levels and astrogliosis marker GFAP.

<p>A. The levels of p53were quantified using immunoblot analysis in the soluble fraction of spinal cord homogenates of SOD^G93A mice treated with BBS or non relevant MAb for 42 days. p53 levels were detected using PAb 240 antibody and normalized to β-Actin. All values are expressed as the mean ± SEM. Statistical comparisons were performed using Student's t-test. N(BBS) = 4, N(Non relevant) = 5. *<i>p</i> < 0.05; **<i>p</i> < 0.01 (v.s. Non relevant). B. Lumber spinal cords were subjected to immunohistochemical analysis. Spinal cord sections were stained with anti-GFAP antibody, and the intensity of the staining was analyzed using Image-J Software. Scale bars in panel B correspond to 1 mm, respectively. Statistical comparisons were performed using Student's t-test. N(BBS) = 5, N(Non relevant) = 5. **<i>p</i> < 0.01 (v.s. Non relevant).